Biora Therapeutics, Inc. Common Stock
BIOR
BIOR was delisted on the 10th of December, 2024.
44 hedge funds and large institutions have $24.1M invested in Biora Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 8 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
85% more call options, than puts
Call options by funds: $1.03M | Put options by funds: $556K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.13% less ownership
Funds ownership: 26.74% → 26.61% (-0.13%)
4% less funds holding
Funds holding: 46 → 44 (-2)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
30% less capital invested
Capital invested by funds: $34.5M → $24.1M (-$10.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$585K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$142K |
| 3 |
Jane Street
New York
|
+$23K |
| 4 |
Wolverine Trading
Chicago,
Illinois
|
+$18.2K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$16.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$241K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$141K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$90.4K |
| 4 |
Morgan Stanley
New York
|
-$39.1K |
| 5 |
EGM
Engineers Gate Manager
New York
|
-$8K |
BIOR Hedge Fund Activity: Q3 2022 in Review
44 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Biora Therapeutics, Inc. Common Stock (BIOR) for Q3 2022, worth a combined $24.1M — down 30% from $34.5M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of BIOR and 7 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 12 added.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $585K. The largest seller was Millennium Management, cutting an estimated $241K.
- 44 institutional investors held Biora Therapeutics, Inc. Common Stock (BIOR) as of Q3 2022, down from 46 in Q2 2022.
- Funds reported $24.1M of Biora Therapeutics, Inc. Common Stock stock for Q3 2022, down 30% quarter-over-quarter.
- 7 funds opened new Biora Therapeutics, Inc. Common Stock positions in Q3 2022 and 8 closed out, a net change of -1 holder.
- The largest Biora Therapeutics, Inc. Common Stock buyer in Q3 2022 was GSA Capital Partners, an estimated $585K added.
- The largest Biora Therapeutics, Inc. Common Stock seller in Q3 2022 was Millennium Management, an estimated $241K sold.
Based on aggregated 13F filings for Q3 2022.